Search

Your search keyword '"Ossenkoppele, Gert"' showing total 1,814 results
Start Over Author "Ossenkoppele, Gert"
1,814 results on '"Ossenkoppele, Gert"'

1. Midostaurin added to 10-day decitabine, for patients unfit for intensive chemotherapy with AML and higher risk MDS, irrespective of FLT3 mutational status, does not improve outcome

Author

Huls, Gerwin, Chitu, Dana A., Tick, Lidwine, Boersma, Rinske, Breems, Dimitri, Herbers, Alexandra, Klein, Saskia K., de Jonge, Suzan, Westerweel, Peter E., Cruijsen, Marjan, Hoogendoorn, Mels, Cuijpers, Marlous, Deeren, Dries, Bailly, Benjamin, Visser, Otto, van Rhenen, Anna, Posthuma, Eduard F. M., Valk, Peter J. M., Cloos, Jacqueline, Ammatuna, Emanuele, Refos, Jeannine M., Fakkert, R., Löwenberg, Bob, and Ossenkoppele, Gert J.

Published
2024
Full Text
View/download PDF

3. Rearrangements involving 11q23.3/KMT2A in adult AML: mutational landscape and prognostic implications – a HARMONY study

Author

Hernández-Sánchez, Alberto, González, Teresa, Sobas, Marta, Sträng, Eric, Castellani, Gastone, Abáigar, María, Valk, Peter J. M., Villaverde Ramiro, Ángela, Benner, Axel, Metzeler, Klaus H., Azibeiro, Raúl, Tettero, Jesse M., Martínez-López, Joaquín, Pratcorona, Marta, Martínez Elicegui, Javier, Mills, Ken I., Thiede, Christian, Sanz, Guillermo, Döhner, Konstanze, Heuser, Michael, Haferlach, Torsten, Turki, Amin T., Reinhardt, Dirk, Schulze-Rath, Renate, Barbus, Martje, Hernández-Rivas, Jesús María, Huntly, Brian, Ossenkoppele, Gert, Döhner, Hartmut, and Bullinger, Lars

Published
2024
Full Text
View/download PDF

4. Bayesian interim analysis for prospective randomized studies: reanalysis of the acute myeloid leukemia HOVON 132 clinical trial

Author

van der Maas, Niek G., Versluis, Jurjen, Nasserinejad, Kazem, van Rosmalen, Joost, Pabst, Thomas, Maertens, Johan, Breems, Dimitri, Manz, Markus, Cloos, Jacqueline, Ossenkoppele, Gert J., Floisand, Yngvar, Gradowska, Patrycja, Löwenberg, Bob, Huls, Gerwin, Postmus, Douwe, Pignatti, Francesco, and Cornelissen, Jan J.

Published
2024
Full Text
View/download PDF

7. Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine

Author

Hilberink, Jacobien R., van Zeventer, Isabelle A., Chitu, Dana A., Pabst, Thomas, Klein, Saskia K., Stussi, Georg, Griskevicius, Laimonas, Valk, Peter J. M., Cloos, Jacqueline, van de Loosdrecht, Arjan A., Breems, Dimitri, van Lammeren-Venema, Danielle, Boersma, Rinske, Jongen-Lavrencic, Mojca, Fehr, Martin, Hoogendoorn, Mels, Manz, Markus G., Söhne, Maaike, van Marwijk Kooy, Rien, Deeren, Dries, van der Poel, Marjolein W. M., Legdeur, Marie Cecile, Tick, Lidwine, Chalandon, Yves, Ammatuna, Emanuele, Blum, Sabine, Löwenberg, Bob, Ossenkoppele, Gert J., and Huls, Gerwin

Published
2023
Full Text
View/download PDF

8. Bimodal expression of potential drug target CLL-1 (CLEC12A) on CD34+ blasts of AML patients.

Author

Ngai, Lok, Ma, Connie, Maguire, Orla, Do, An, Robert, Alberto, Logan, Aaron, Griffiths, Elizabeth, Nemeth, Michael, Green, Cherie, Pourmohamad, Tony, van Kuijk, Bo, Snel, Alexander, Kwidama, Zinia, Venniker-Punt, Bianca, Cooper, James, Manz, Markus, Gjertsen, Bjørn, Smit, Linda, Ossenkoppele, Gert, Janssen, Jeroen, Cloos, Jacqueline, and Sumiyoshi, Teiko

Subjects
CD34+ blasts, CLL-1, acute myeloid leukemia, bimodality, bone marrow aspirates, flow cytometry, Antigens, CD34, Biomarkers, Tumor, Bone Marrow Cells, Cytogenetic Analysis, Female, Flow Cytometry, Gene Expression Profiling, Gene Expression Regulation, Leukemic, Hematopoietic Stem Cells, Humans, Immunophenotyping, Lectins, C-Type, Leukemia, Myeloid, Acute, Male, Middle Aged, Mutation, Myeloid Cells, Precursor Cells, B-Lymphoid, Primary Cell Culture, Receptors, Mitogen
Abstract

OBJECTIVES: This study aims to retrospectively assess C-lectin-like molecule 1 (CLL-1) bimodal expression on CD34+ blasts in acute myeloid leukemia (AML) patients (total N = 306) and explore potential CLL-1 bimodal associations with leukemia and patient-specific characteristics. METHODS: Flow cytometry assays were performed to assess the deeper immunophenotyping of CLL-1 bimodality. Cytogenetic analysis was performed to characterize the gene mutation on CLL-1-negative subpopulation of CLL-1 bimodal AML samples. RESULTS: The frequency of a bimodal pattern of CLL-1 expression of CD34+ blasts ranged from 8% to 65% in the different cohorts. Bimodal CLL-1 expression was most prevalent in patients with MDS-related AML (P = .011), ELN adverse risk (P = .002), NPM1 wild type (WT, P = .049), FLT3 WT (P = .035), and relatively low percentages of leukemia-associated immunophenotypes (P = .006). Additional immunophenotyping analysis revealed the CLL-1- subpopulation may consist of pre-B cells, immature myeloblasts, and hematopoietic stem cells. Furthermore, (pre)-leukemic mutations were detected in both CLL-1+ and CLL-1- subfractions of bimodal samples (N = 3). CONCLUSIONS: C-lectin-like molecule 1 bimodality occurs in about 25% of AML patients and the CLL-1- cell population still contains malignant cells, hence it may potentially limit the effectiveness of CLL-1-targeted therapies and warrant further investigation.

Published
2021

9. Acute promyelocytic leukemia: long-term outcomes from the HARMONY project

Author

Voso, Maria Teresa, Guarnera, Luca, Lehmann, Söhren, Döhner, Konstanze, Döhner, Hartmut, Platzbecker, Uwe, Russell, Nigel, Dillon, Richard, Thomas, Ian, Ossenkoppele, Gert, Haferlach, Torsten, Vignetti, Marco, la Sala, Edoardo, Piciocchi, Alfonso, Fazi, Paola, Ramiro, Angela Villaverde, Giménez, Laura Tur, Gurnari, Carmelo, Bullinger, Lars, and Hernández Rivas, Jesús María

Published
2024
Full Text
View/download PDF

12. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN

Author

Döhner, Hartmut, Wei, Andrew H., Appelbaum, Frederick R., Craddock, Charles, DiNardo, Courtney D., Dombret, Hervé, Ebert, Benjamin L., Fenaux, Pierre, Godley, Lucy A., Hasserjian, Robert P., Larson, Richard A., Levine, Ross L., Miyazaki, Yasushi, Niederwieser, Dietger, Ossenkoppele, Gert, Röllig, Christoph, Sierra, Jorge, Stein, Eytan M., Tallman, Martin S., Tien, Hwei-Fang, Wang, Jianxiang, Wierzbowska, Agnieszka, and Löwenberg, Bob

Published
2022
Full Text
View/download PDF

15. Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome

Author

Grob, Tim, Al Hinai, Adil S.A., Sanders, Mathijs A., Kavelaars, François G., Rijken, Melissa, Gradowska, Patrycja L., Biemond, Bart J., Breems, Dimitri A., Maertens, Johan, van Marwijk Kooy, Marinus, Pabst, Thomas, de Weerdt, Okke, Ossenkoppele, Gert J., van de Loosdrecht, Arjan A., Huls, Gerwin A., Cornelissen, Jan J., Beverloo, H. Berna, Löwenberg, Bob, Jongen-Lavrencic, Mojca, and Valk, Peter J.M.

Published
2022
Full Text
View/download PDF

17. Safety and tolerability of AMG 330 in adults with relapsed/refractory AML: a phase 1a dose-escalation study.

Author

Ravandi, Farhad, Subklewe, Marion, Walter, Roland B., Vachhani, Pankit, Ossenkoppele, Gert, Buecklein, Veit, Döhner, Hartmut, Jongen-Lavrencic, Mojca, Baldus, Claudia D., Fransecky, Lars, Pardee, Timothy S., Kantarjian, Hagop, Yen, Priscilla K., Mukundan, Lata, Panwar, Bharat, Yago, Marc R., Agarwal, Suresh, Khaldoyanidi, Sophia K., and Stein, Anthony

Subjects
CYTOKINE release syndrome, ACUTE myeloid leukemia, ADVERSE health care events, CANCER remission, CYTOTOXINS
Abstract

AMG 330, a bispecific T-cell engager (BiTE®) that binds CD33 and CD3 on T cells facilitates T-cell–mediated cytotoxicity against CD33+ cells. This first-in-human, open-label, dose-escalation study evaluated the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of AMG 330 in adults with relapsed/refractory acute myeloid leukemia (R/R AML). Amongst 77 patients treated with AMG 330 (0.5 µg/day–1.6 mg/day) on 14-day or 28-day cycles, maximum tolerated dose was not reached; median duration of treatment was 29 days. The most frequent treatment-related adverse events were cytokine release syndrome (CRS; 78%) and rash (30%); 10% of patients experienced grade 3/4 CRS. CRS was mitigated with stepwise dosing of AMG 330, prophylactic dexamethasone, and early treatment with tocilizumab. Among 60 evaluable patients, eight achieved complete remission or morphologic leukemia-free state; of the 52 non-responders, 37% had ≥50% reduction in AML bone marrow blasts. AMG 330 is a promising CD33-targeted therapeutic strategy for R/R AML. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations

Author

Döhner, Hartmut, DiNardo, Courtney D., Appelbaum, Frederick R., Craddock, Charles, Dombret, Hervé, Ebert, Benjamin L., Fenaux, Pierre, Godley, Lucy A., Hasserjian, Robert P., Larson, Richard A., Levine, Ross L., Miyazaki, Yasushi, Niederwieser, Dietger, Ossenkoppele, Gert, Röllig, Christoph, Sierra, Jorge, Stein, Eytan M., Tallman, Martin S., Tien, Hwei-Fang, Wang, Jianxiang, Wierzbowska, Agnieszka, Wei, Andrew H., and Löwenberg, Bob

Abstract

The European LeukemiaNet (ELN) genetic risk classifications were developed based on data from younger adults receiving intensive chemotherapy. Emerging analyses from patients receiving less-intensive therapies prompted a proposal for an ELN genetic risk classification specifically for this patient population.

Published
2024
Full Text
View/download PDF

23. Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial

Author

Löwenberg, Bob, Pabst, Thomas, Maertens, Johan, Gradowska, Patrycja, Biemond, Bart J., Spertini, Olivier, Vellenga, Edo, Griskevicius, Laimonas, Tick, Lidwine W., Jongen-Lavrencic, Mojca, van Marwijk Kooy, Marinus, Vekemans, Marie-Christiane, van der Velden, Walter J.F.M., Beverloo, Berna, Michaux, Lucienne, Graux, Carlos, Deeren, Dries, de Weerdt, Okke, van Esser, Joost W.J., Bargetzi, Mario, Klein, Saskia K., Gadisseur, Alain, Westerweel, Peter E., Veelken, Hendrik, Gregor, Michael, Silzle, Tobias, van Lammeren-Venema, Daniëlle, Moors, Ine, Breems, Dimitri A., Hoogendoorn, Mels, Legdeur, Marie-Cecile J.C., Fischer, Thomas, Kuball, Juergen, Cornelissen, Jan, Porkka, Kimmo, Juliusson, Gunnar, Meyer, Peter, Höglund, Martin, Gjertsen, Bjorn T., Janssen, Jeroen J.W.M., Huls, Gerwin, Passweg, Jakob, Cloos, Jacqueline, Valk, Peter J.M., van Elssen, Catharina H.M.J., Manz, Markus G., Floisand, Yngvar, and Ossenkoppele, Gert J.

Published
2021
Full Text
View/download PDF

24. Rearrangements involving 11q23.3/KMT2A in adult AML:mutational landscape and prognostic implications - a HARMONY study

Author

Hernandez-Sanchez, Alberto, Gonzalez, Teresa, Sobas, Marta, Straeng, Eric, Castellani, Gastone, Abaigar, Maria, Valk, Peter J. M., Ramiro, Angela Villaverde, Benner, Axel, Metzeler, Klaus H., Azibeiro, Raul, Tettero, Jesse M., Martinez-Lopez, Joaquin, Pratcorona, Marta, Elicegui, Javier Martinez, Mills, Ken I., Thiede, Christian, Sanz, Guillermo, Doehner, Konstanze, Heuser, Michael, Haferlach, Torsten, Turki, Amin T., Reinhardt, Dirk, Schulze-Rath, Renate, Barbus, Martje, Hernandez-Rivas, Jesus Maria, Huntly, Brian, Ossenkoppele, Gert, Doehner, Hartmut, Bullinger, Lars, Hernandez-Sanchez, Alberto, Gonzalez, Teresa, Sobas, Marta, Straeng, Eric, Castellani, Gastone, Abaigar, Maria, Valk, Peter J. M., Ramiro, Angela Villaverde, Benner, Axel, Metzeler, Klaus H., Azibeiro, Raul, Tettero, Jesse M., Martinez-Lopez, Joaquin, Pratcorona, Marta, Elicegui, Javier Martinez, Mills, Ken I., Thiede, Christian, Sanz, Guillermo, Doehner, Konstanze, Heuser, Michael, Haferlach, Torsten, Turki, Amin T., Reinhardt, Dirk, Schulze-Rath, Renate, Barbus, Martje, Hernandez-Rivas, Jesus Maria, Huntly, Brian, Ossenkoppele, Gert, Doehner, Hartmut, and Bullinger, Lars

Abstract

Balanced rearrangements involving the KMT2A gene (KMT2Ar) are recurrent genetic abnormalities in acute myeloid leukemia (AML), but there is lack of consensus regarding the prognostic impact of different fusion partners. Moreover, prognostic implications of gene mutations co-occurring with KMT2Ar are not established. From the HARMONY AML database 205 KMT2Ar adult patients were selected, 185 of whom had mutational information by a panel-based next-generation sequencing analysis. Overall survival (OS) was similar across the different translocations, including t(9;11)(p21.3;q23.3)/KMT2A::MLLT3 (p = 0.756). However, independent prognostic factors for OS in intensively treated patients were age >60 years (HR 2.1, p = 0.001), secondary AML (HR 2.2, p = 0.043), DNMT3A-mut (HR 2.1, p = 0.047) and KRAS-mut (HR 2.0, p = 0.005). In the subset of patients with de novo AML < 60 years, KRAS and TP53 were the prognostically most relevant mutated genes, as patients with a mutation of any of those two genes had a lower complete remission rate (50% vs 86%, p < 0.001) and inferior OS (median 7 vs 30 months, p < 0.001). Allogeneic hematopoietic stem cell transplantation in first complete remission was able to improve OS (p = 0.003). Our study highlights the importance of the mutational patterns in adult KMT2Ar AML and provides new insights into more accurate prognostic stratification of these patients. (Figure presented.).

Published
2024

25. The role of the primitive marker CD133 in CD34-negative acute myeloid leukemia for the detection of leukemia stem cells

Author

Reuvekamp, Tom, Janssen, Luca L. G., Ngai, Lok Lam, Carbaat-Ham, Jannemieke, den Hartog, Daphne, Scholten, Willemijn J., Kelder, Angele, Hanekamp, Diana, Wensink, Eliza, van Gils, Noortje, Gradowska, Patrycja, Lowenberg, Bob, Ossenkoppele, Gert J., van de Loosdrecht, Arjan A., Westers, Theresia M., Smit, Linda, Bachas, Costa, Cloos, Jacqueline, Reuvekamp, Tom, Janssen, Luca L. G., Ngai, Lok Lam, Carbaat-Ham, Jannemieke, den Hartog, Daphne, Scholten, Willemijn J., Kelder, Angele, Hanekamp, Diana, Wensink, Eliza, van Gils, Noortje, Gradowska, Patrycja, Lowenberg, Bob, Ossenkoppele, Gert J., van de Loosdrecht, Arjan A., Westers, Theresia M., Smit, Linda, Bachas, Costa, and Cloos, Jacqueline

Abstract

The most important reason for dismal outcomes in acute myeloid leukemia (AML) is the development of relapse. Leukemia stem cells (LSCs) are hypothesized to initiate relapse, and high CD34+CD38- LSC load is associated with poor prognosis. In 10% of AML patients, CD34 is not or is low expressed on the leukemic cells (<1%), and CD34+CD38- LSCs are absent. These patients are classified as CD34-negative. We aimed to determine whether the primitive marker CD133 can detect LSCs in CD34-negative AML. We retrospectively quantified 148 CD34-negative patients for proportions of CD34-CD133+ and CD133+CD38- cell fractions in the diagnostic samples of CD34-negative patients in the HOVON102 and HOVON132 trials. No prognostic difference was found between patients with high or low proportions of CD34-CD133+, which is found to be aberrantly expressed in AML. A high level of CD133+CD38- cells was not associated with poor overall survival, and expression in AML was similar to normal bone marrow. To conclude, CD133 is useful as an additional primitive marker for the detection of leukemic blast cells in CD34-negative AML. However, CD133+CD38 alone is not suitable for the detection of LSCs at diagnosis.

Published
2024

26. European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia : Final Analysis and Novel Prognostic Factors for Treatment-Free Remission

Author

Mahon, Francois-Xavier, Pfirrmann, Markus, Dulucq, Stephanie, Hochhaus, Andreas, Panayiotidis, Panayiotis, Almeida, Antonio, Mayer, Jiri, Hjorth-Hansen, Henrik, Janssen, Jeroen J. W. M., Mustjoki, Satu, Martinez-Lopez, Joaquin, Vestergaard, Hanne, Ehrencrona, Hans, Polakova, Katerina Machova, Olsson-Strömberg, Ulla, Ossenkoppele, Gert, Berger, Marc G., Etienne, Gabriel, Dengler, Jolanta, Bruemmendorf, Tim H., Burchert, Andreas, Rea, Delphine, Rousselot, Philippe, Nicolini, Franck E., Hofmann, Wolf-Karsten, Richter, Johan, Saussele, Susanne, Mahon, Francois-Xavier, Pfirrmann, Markus, Dulucq, Stephanie, Hochhaus, Andreas, Panayiotidis, Panayiotis, Almeida, Antonio, Mayer, Jiri, Hjorth-Hansen, Henrik, Janssen, Jeroen J. W. M., Mustjoki, Satu, Martinez-Lopez, Joaquin, Vestergaard, Hanne, Ehrencrona, Hans, Polakova, Katerina Machova, Olsson-Strömberg, Ulla, Ossenkoppele, Gert, Berger, Marc G., Etienne, Gabriel, Dengler, Jolanta, Bruemmendorf, Tim H., Burchert, Andreas, Rea, Delphine, Rousselot, Philippe, Nicolini, Franck E., Hofmann, Wolf-Karsten, Richter, Johan, and Saussele, Susanne

Abstract

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.The European Stop Kinase Inhibitors (EURO-SKI) study is the largest clinical trial for investigating the cessation of tyrosine kinase inhibitors (TKIs) in patients with chronic myeloid leukemia in stable deep molecular remission (DMR). Among 728 patients, 434 patients (61%; 95% CI, 57 to 64) remained in major molecular response (MMR) at 6 months and 309 patients of 678 (46%; 95% CI, 42 to 49) at 36 months. Duration of TKI treatment and DMR before TKI stop were confirmed as significant factors for the prediction of MMR loss at 6 months. In addition, the type of BCR::ABL1 transcript was identified as a prognostic factor. For late MMR losses after 6 months, TKI treatment duration, percentage of blasts in peripheral blood, and platelet count at diagnosis were significant factors in multivariate analysis. For the entire study period of 36 months, multiple logistic regression models confirmed duration of treatment, blasts, and transcript type as independent factors for MMR maintenance. In addition to the duration of treatment, transcript type as well as blasts in peripheral blood at diagnosis should be considered as important factors to predict treatment-free remission.

Published
2024
Full Text
View/download PDF

27. Bayesian interim analysis for prospective randomized studies:reanalysis of the acute myeloid leukemia HOVON 132 clinical trial

Author

van der Maas, Niek G., Versluis, Jurjen, Nasserinejad, Kazem, van Rosmalen, Joost, Pabst, Thomas, Maertens, Johan, Breems, Dimitri, Manz, Markus, Cloos, Jacqueline, Ossenkoppele, Gert J., Floisand, Yngvar, Gradowska, Patrycja, Löwenberg, Bob, Huls, Gerwin, Postmus, Douwe, Pignatti, Francesco, Cornelissen, Jan J., van der Maas, Niek G., Versluis, Jurjen, Nasserinejad, Kazem, van Rosmalen, Joost, Pabst, Thomas, Maertens, Johan, Breems, Dimitri, Manz, Markus, Cloos, Jacqueline, Ossenkoppele, Gert J., Floisand, Yngvar, Gradowska, Patrycja, Löwenberg, Bob, Huls, Gerwin, Postmus, Douwe, Pignatti, Francesco, and Cornelissen, Jan J.

Abstract

Randomized controlled trials (RCTs) are the gold standard to establish the benefit-risk ratio of novel drugs. However, the evaluation of mature results often takes many years. We hypothesized that the addition of Bayesian inference methods at interim analysis time points might accelerate and enforce the knowledge that such trials may generate. In order to test that hypothesis, we retrospectively applied a Bayesian approach to the HOVON 132 trial, in which 800 newly diagnosed AML patients aged 18 to 65 years were randomly assigned to a “7 + 3” induction with or without lenalidomide. Five years after the first patient was recruited, the trial was negative for its primary endpoint with no difference in event-free survival (EFS) between experimental and control groups (hazard ratio [HR] 0.99, p = 0.96) in the final conventional analysis. We retrospectively simulated interim analyses after the inclusion of 150, 300, 450, and 600 patients using a Bayesian methodology to detect early lack of efficacy signals. The HR for EFS comparing the lenalidomide arm with the control treatment arm was 1.21 (95% CI 0.81–1.69), 1.05 (95% CI 0.86–1.30), 1.00 (95% CI 0.84–1.19), and 1.02 (95% CI 0.87–1.19) at interim analysis 1, 2, 3 and 4, respectively. Complete remission rates were lower in the lenalidomide arm, and early deaths more frequent. A Bayesian approach identified that the probability of a clinically relevant benefit for EFS (HR < 0.76, as assumed in the statistical analysis plan) was very low at the first interim analysis (1.2%, 0.6%, 0.4%, and 0.1%, respectively). Similar observations were made for low probabilities of any benefit regarding CR. Therefore, Bayesian analysis significantly adds to conventional methods applied for interim analysis and may thereby accelerate the performance and completion of phase III trials.

Published
2024

31. EHA evaluation of the ESMO—Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies

Author

Kiesewetter, Barbara, Cherny, Nathan I., Boissel, Nicolas, Cerisoli, Francesco, Dafni, Urania, de Vries, Elisabeth G.E., Ghia, Paolo, Gökbuget, Nicola, González-Calle, Verónica, Huntly, Brian, Jäger, Ulrich, Latino, Nicola Jane, Douillard, Jean-Yves, Malcovati, Luca, Mateos, Mría-Victoria., Ossenkoppele, Gert J., Porkka, Kimmo, Raderer, Markus, Ribera, Josep-Maria, Scarfò, Lydia, Wester, Ruth, Zygoura, Panagiota, and Sonneveld, Pieter

Published
2020
Full Text
View/download PDF

32. Optimal Prognostic Threshold for Acute Myeloid Leukemia (AML) Measurable Residual Disease (MRD) Positivity By Multiparameter Flow Cytometry: A Report of 2,051 Patients from MRC/NCRI, Gimema, HOVON, and Seattle

Author

Rodríguez-Arbolí, Eduardo, primary, Othus, Megan, additional, Freeman, Sylvie, additional, Buccisano, Francesco, additional, Ngai, Lok Lam, additional, Thomas, Ian, additional, Palmieri, Raffaele, additional, Cloos, Jacqueline, additional, Johnson, Sean, additional, Meddi, Elisa, additional, Russell, Nigel H., additional, Venditti, Adriano, additional, Gradowska, Patrycja, additional, Ossenkoppele, Gert J., additional, Lowenberg, Bob, additional, and Walter, Roland B., additional

Published
2024
Full Text
View/download PDF

33. Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study

Author

Montesinos, Pau, Roboz, Gail J., Bulabois, Claude-Eric, Subklewe, Marion, Platzbecker, Uwe, Ofran, Yishai, Papayannidis, Cristina, Wierzbowska, Agnieszka, Shin, Ho Jin, Doronin, Vadim, Deneberg, Stefan, Yeh, Su-Peng, Ozcan, Mehmet Ali, Knapper, Steven, Cortes, Jorge, Pollyea, Daniel A., Ossenkoppele, Gert, Giralt, Sergio, Döhner, Hartmut, Heuser, Michael, Xiu, Liang, Singh, Indrajeet, Huang, Fei, Larsen, Julie S., and Wei, Andrew H.

Published
2021
Full Text
View/download PDF

34. The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia

Author

Pfirrmann, Markus, Clark, Richard E., Prejzner, Witold, Lauseker, Michael, Baccarani, Michele, Saussele, Susanne, Guilhot, François, Heibl, Sonja, Hehlmann, Rüdiger, Faber, Edgar, Turkina, Anna, Ossenkoppele, Gert, Höglund, Martin, Zaritskey, Andrey, Griskevicius, Laimonas, Olsson-Strömberg, Ulla, Everaus, Hele, Koskenvesa, Perttu, Labar, Boris, Sacha, Tomasz, Zackova, Daniela, Cervantes, Francisco, Colita, Adriana, Zupan, Irena, Bogdanovic, Andrija, Castagnetti, Fausto, Guilhot, Joëlle, Hasford, Joerg, Hochhaus, Andreas, and Hoffmann, Verena S.

Published
2020
Full Text
View/download PDF

42. Prognostic Significance of Measurable Residual Disease Detection by Flow Cytometry in Autologous Stem Cell Apheresis Products in AML

Author

Tettero, Jesse M., primary, Buisman, Yara, additional, Ngai, Lok Lam, additional, Bachas, Costa, additional, Gjertsen, Bjorn T., additional, Kelder, Angèle, additional, van de Loosdrecht, Arjan A., additional, Manz, Markus G., additional, Pabst, Thomas, additional, Scholten, Willemijn, additional, Ossenkoppele, Gert J., additional, Cloos, Jacqueline, additional, and de Leeuw, David C., additional

Published
2023
Full Text
View/download PDF

44. Prospective validation of the prognostic relevance of CD34+CD38– AML stem cell frequency in the HOVON-SAKK132 trial

Author

Ngai, Lok Lam, Hanekamp, Diana, Janssen, Fleur, Carbaat-Ham, Jannemieke, Hofland, Maaike A M, Fayed, Mona M H E, Kelder, Angèle, Oudshoorn-van Marsbergen, Laura, Scholten, Willemijn J, Snel, Alexander N, Bachas, Costa, Tettero, Jesse M, Breems, Dimitri A, Fischer, Thomas, Gjertsen, Bjorn T, Griskevicius, Laimonas, Juliusson, Gunnar, van de Loosdrecht, Arjan A, Maertens, Johan A, Manz, Markus G, Pabst, Thomas, Passweg, Jakob R, Porkka, Kimmo, Valk, Peter J M, Gradowska, Patrycja, Löwenberg, Bob, de Leeuw, David C, Janssen, Jeroen J W M, Ossenkoppele, Gert J, Cloos, Jacqueline, Hematology laboratory, VU University medical center, Hematology, AII - Cancer immunology, AII - Inflammatory diseases, CCA - Cancer biology and immunology, CCA - Imaging and biomarkers, and CCA - Cancer Treatment and quality of life

Subjects
All institutes and research themes of the Radboud University Medical Center, Immunology, Cell Biology, Hematology, 610 Medicine & health, Biochemistry, Rare cancers Radboud Institute for Health Sciences [Radboudumc 9]
Abstract

Item does not contain fulltext

Published
2023
Full Text
View/download PDF

46. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party

Author

Schuurhuis, Gerrit J., Heuser, Michael, Freeman, Sylvie, Béné, Marie-Christine, Buccisano, Francesco, Cloos, Jacqueline, Grimwade, David, Haferlach, Torsten, Hills, Robert K., Hourigan, Christopher S., Jorgensen, Jeffrey L., Kern, Wolfgang, Lacombe, Francis, Maurillo, Luca, Preudhomme, Claude, van der Reijden, Bert A., Thiede, Christian, Venditti, Adriano, Vyas, Paresh, Wood, Brent L., Walter, Roland B., Döhner, Konstanze, Roboz, Gail J., and Ossenkoppele, Gert J.

Published
2018
Full Text
View/download PDF

48. CD34+CD38− leukemic stem cell frequency to predict outcome in acute myeloid leukemia

Author

Zeijlemaker, Wendelien, Grob, Tim, Meijer, Rosa, Hanekamp, Diana, Kelder, Angèle, Carbaat-Ham, Jannemieke C., Oussoren-Brockhoff, Yvonne J. M., Snel, Alexander N., Veldhuizen, Dennis, Scholten, Willemijn J., Maertens, Johan, Breems, Dimitri A., Pabst, Thomas, Manz, Markus G., van der Velden, Vincent H. J., Slomp, Jennichjen, Preijers, Frank, Cloos, Jacqueline, van de Loosdrecht, Arjan A., Löwenberg, Bob, Valk, Peter J. M., Jongen-Lavrencic, Mojca, Ossenkoppele, Gert J., and Schuurhuis, Gerrit J.

Published
2019
Full Text
View/download PDF

49. S136: ANALYSIS OF FACTORS ASSOCIATED WITH LONG-TERM SURVIVAL IN A LARGE ACUTE PROMYELOCYTIC LEUKEMIA (APL) PATIENT COHORT: A HARMONY ALLIANCE STUDY

Author

Guarnera, Luca, primary, Lehmann, Soren, additional, Döhner, Konstanze, additional, Döhner, Hartmut, additional, Ossenkoppele, Gert, additional, Russell, Nigel, additional, Dillon, Richard, additional, Platzbecker, Uwe, additional, Vignetti, Marco, additional, la Sala, Edoardo, additional, Villaverde, Angela, additional, Tur, Laura, additional, Hernández Rivas, Jesus, additional, and Teresa Voso, Maria, additional

Published
2023
Full Text
View/download PDF

50. P565: REAL-WORLD DATA AS SUPPLEMENTARY CONTROLS FOR THE PROSPECTIVE RANDOMIZED HOVON-103 TRIAL IN INTENSIVELY TREATED ELDERLY ACUTE MYELOID LEUKEMIA PATIENTS

Author

Hermans, Sjoerd, primary, van Norden, Yvette, additional, van Werkhoven, Erik, additional, Dinmohamed, Avinash, additional, Huijgens, Peter, additional, Ossenkoppele, Gert, additional, Huls, Gerwin, additional, Löwenberg, Bob, additional, Pabst, Thomas, additional, Breems, Dimitri, additional, Postmus, Douwe, additional, Pignatti, Francesco, additional, Versluis, Jurjen, additional, and Cornelissen, Jan, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results